News

GBS is a rare, acute and antibody-mediated autoimmune disease that will affect the peripheral nervous system. The disease currently has no approved therapies in the US. Earlier, the

The mid-stage trial met the primary endpoint by recording a statistically significant improvement from baseline in motor symptoms in patients treated with tavapadon in comparison with those in

The opinion was based on positive findings from the Phase III JAVELIN Renal 101 study, which demonstrated a significant extension in median progression-free survival (PFS) and a clinically

“There is a pressing need for effective treatments for patients suffering from the profound defects associated with FAOD, and we believe REN001 represents a promising new therapy. Orphan

The FDA has approved new drug applications (sNDAs) for Pifeltro in combination with other antiretroviral agents and Delstrigo as a complete regimen for adult patients with HIV-1 infection

The partnership will see compounds from the retinal disease pipeline portfolio of Boehringer Ingelheim combined with the intravitreal (IVT) drug delivery technologies of Inflammasome. Inflammasome’s technology will be

The status was provided based on clinical results of SB623, including the phase 2 study of modified stem cells in traumatic brain injury (STEMTRA) trial. SB623 is a

LINZESS was approved by the National Medical Products Administration for adults with IBS-C in China in January 2019. LINZESS is expected to be launched in China in the

GB-102, a pan-Vascular Endothelial Growth Factor (VEGF) inhibitor and potential twice-per-year therapy is targeted to reduce the need for frequent intravitreal injections in retinal diseases, including wet AMD,